Skip to Main Content

A version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

The 27 senators who sit on the Senate Finance Committee are set to grill seven drug company executives Tuesday morning about high prescription drug prices. STAT spoke with lawmakers in both parties about what they plan to ask, what they hope to hear, and what answers they won’t accept. Below are five major takeaways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

    • The FDA only has authority over safety and efficacy. They have no say regarding business practices. Pharmaceutical companies have basically a free reign when it comes to drug pricing , price fixing , drug wastage , and starving off generic and biosimilar competition. We need a watchdog agency like NICE in the UK.

Comments are closed.